Skip to main content
. 2020 Nov 2;5(1):pkaa085. doi: 10.1093/jncics/pkaa085

Table 2.

Laboratory measures according to cancer status

Laboratory measure nused/navailable Noncancer mean (SE)a Cancer mean (SE)a P b
Hemoglobin, g/dL 5514/5553 13.02 (0.03) 11.90 (0.10) <.001
Red blood cell, ×106/μL 5503/5553 4.42 (0.01) 4.06 (0.04) <.001
Platelet, ×103/μL 5446/5532 224.63 (1.4) 213.71 (4.49) .02
White blood cell, ×103/μL 5495/5551 8.39 (0.06) 7.68 (0.20) <.001
Lymphocyte, ×103/μL 5356/5388 1.08 (0.01) 0.99 (0.03) .005
Lymphocyte, % 5438/5518 14.45 (0.13) 14.23 (0.42) .61
Eosinophil, ×103/μL 5321/5388 0.03 (0.001) 0.03 (0.002) .89
Eosinophil, % 5406/5493 0.43 (0.01) 0.43 (0.03) .88
Basophil, ×103/μL 5332/5388 0.012 (0.001) 0.009 (0.002) .08
Basophil, % 5405/5492 0.29 (0.01) 0.26 (0.02) .10
Monocyte, ×103/μL 5334/5388 0.55 (0.004) 0.51 (0.02) .01
Monocyte, % 5458/5517 7.17 (0.06 ) 7.41 (0.18) .20
Neutrophil, ×103/μL 5482/5544 6.70 (0.06) 6.07 (0.19) .002
Neutrophil, % 5441/5518 76.64 (0.17) 76.17 (0.56) .42
Serum creatinine, mg/dL 5376/5519 1.52 (0.02) 1.37 (0.07) .03
Ferritin, ng/mL 4142/4222 1160.61 (23.84) 1162.62 (73.85) .97
Percent D-dimer, μg/mL FEU 4126/4126 .13
 <0.50 9.8 9.3
 ≥0.50 90.2 90.7
Partial thromboplastin time, s 3390/3456 33.00 (0.12) 33.01 (0.37) 1.0
Prothrombin time, s 3474/3527 14.84 (0.05) 14.97 (0.14) .39
C-reactive protein, mg/L 4254/4279 128.52 (1.63) 120.66 (5.03) .14
Fibrinogen, mg/dL 2540/2551 626.85 (4.31) 588.85 (12.47) .004
TNF-alpha, pg/mL 1316/1226 25.94 (0.55) 25.78 (1.41) .92
IL-6, pg/mL 2506/2508 178.51 (13.46) 138.35 (37.72) .31
IL-8, pg/mL 1331/1333 74.56 (4.84) 70.56 (12.30) .76
Percent IL-1β, pg/mL 1330/1330 .99
 <0.4 42.4 41.2
 0.4-0.5 21.4 21.2
 0.6-0.9 16.7 17.7
 ≥0.9 19.3 19.9
a

Values adjusted for age, sex, and number of comorbidities. IL = interleukin; TNF = tumor necrosis factor.

b

P values based on logistic regression for categorical variables and linear regression for continuous variables, adjusted for age, sex, and number of comorbidities.